Takeaways: This acquisition turbocharges Hims & Hers’ Canada growth by giving it a ready-made weight-management business and local provider network, while it becomes the first Canadian...
Takeaways Hims & Hers is using generic semaglutide to anchor its Canadian weight‑loss and metabolic program, giving it a priced‑in, recurring revenue product at about CAD 149/month that...
For most of modern medicine, the pharmaceutical industry has operated largely within a reactive healthcare model, developing therapies designed to treat diseases after they emerge. Today, however, adv...
Takeaways: Felix is positioning itself as the price‑breaker in Canada’s GLP‑1 obesity market, using cheaper semaglutide (as generics arrive) to tackle the main dropout driver and convert strong ...
Precision medicine is often defined by breakthrough therapies and targeted treatments, but behind many of these advances lies a less visible yet increasingly essential component: companion diagnostics...
The pharmaceutical industry has long occupied a complex position in public perception, celebrated for life saving innovation yet frequently criticized for pricing practices, transparency concerns, and...
